Evogene to Present Its Pharma Division Achievements at the BIO International Convention
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will present its pharma division achievements at the BIO International Convention in San Diego, held June 22-25, 2026. The company will highlight AI-driven small-molecule discovery, including its ChemPass AI platform, and management will be available for one-on-one investor meetings.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – EVGN
On the day this news was published, EVGN gained 0.94%, reflecting a mild positive market reaction. Argus tracked a peak move of +11.2% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $60K to the company's valuation, bringing the market cap to $6.44M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EVGN fell 5.82% while peers were mixed: ERNA down 6.81%, LYRA flat, KZIA flat, but MBIO and MBRX up 9.39% and 1.65%. Moves do not indicate a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Phase 1 results | Positive | -13.6% | Reported successful first-in-human Phase 1 BMC128 study with preliminary anti-tumor signals. |
| May 20 | Earnings report | Negative | -7.3% | Q1 2026 revenue fell sharply and net loss widened versus prior year. |
| May 12 | Industry presentation | Neutral | -2.0% | Announced presentation on GenAI molecule design at Schrödinger user group meeting. |
| May 07 | Earnings scheduling | Neutral | -1.3% | Scheduled release date and call details for Q1 2026 financial results. |
| Apr 02 | Nasdaq notice | Negative | -0.4% | Disclosed Nasdaq noncompliance with $1.00 minimum bid price and cure-period timeline. |
Recent news, including positive clinical and AI-platform updates, has often been met with selling, while clearly negative items like weak earnings and a Nasdaq notice also saw downside, suggesting a bias toward selling into most catalysts.
Over the last few months, Evogene has reported a Nasdaq minimum bid price deficiency, scheduled and then released weak Q1 2026 earnings with sharply lower revenue and higher losses, and highlighted its AI-driven capabilities at industry meetings. A key milestone was successful completion of a Phase 1 study of BMC128 with preliminary anti-tumor signals. Despite some positive operational and clinical developments, each event saw negative 24-hour price reactions, framing today’s conference-presentation news against a backdrop of persistent pressure.
Regulatory & Risk Context
An effective Form F-3 filed on March 26, 2026 registers 5,076,924 ordinary shares for resale upon warrant exercise. The company would receive $6.35 million if all warrants are exercised for cash, but does not receive proceeds from secondary resales by the selling shareholder.
Market Pulse Summary
This announcement highlights Evogene’s plan to showcase recent pharma-division achievements and its ChemPass AI™ capabilities at the BIO International Convention on June 22–25, 2026. In recent months, the company reported weak Q1 2026 financials, a Nasdaq minimum bid notice, and both clinical and AI-platform updates, each followed by modest-to-significant declines. Investors may watch future financial filings, clinical milestones, and any collaborations emerging from this conference for clearer impact.
AI-generated analysis. Not financial advice.
Conference to be held in
REHOVOT,
Attending the conference on behalf of Evogene will be Ofer Haviv, President and Chief Executive Officer, Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development.
At the conference, Evogene will present the latest achievements of its pharma division. Dr. Tarcic will deliver an oral presentation highlighting the company's recent technological and scientific breakthroughs in AI-driven small-molecule discovery and optimization and will share insights into how ChemPass AI™ is enabling new opportunities for collaborative drug discovery with pharmaceutical and biotech partners.
Presentation Details:
- Session: Company Presentation
- Date/Time: Tuesday, June 23, 2026 | 2:00 PM PT
- Location: Theater 1
The company's management will be available for one-on-one meetings at the conference. Interested parties are encouraged to contact Evogene's investor or public relations team.
For more details on the conference, please visit: https://convention.bio.org/.
About Evogene Ltd.
Evogene Ltd. (NASDAQ/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Forward-Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene uses forward-looking statements in this press release when it discusses ChemPass AI™ as an enabler of new opportunities for collaborative drug discovery with pharmaceutical and biotech partners. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact
ir@evogene.com
Tel: +972-8-9311901
View original content to download multimedia:https://www.prnewswire.com/news-releases/evogene-to-present-its-pharma-division-achievements-at-the-bio-international-convention-302795111.html
SOURCE Evogene